It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The 5’ cap, catalyzed by RNA guanylyltransferase and 5’-phosphatase (RNGTT), is a vital mRNA modification for the functionality of mRNAs. mRNA capping occurs in the nucleus for the maturation of the functional mRNA and in the cytoplasm for fine-tuning gene expression. Given the fundamental importance of RNGTT in mRNA maturation and expression there is a need to further investigate the regulation of RNGTT. N6-methyladenosine (m6A) is one of the most abundant RNA modifications involved in the regulation of protein translation, mRNA stability, splicing, and export. We sought to investigate whether m6A could regulate the expression and activity of RNGTT. In this short report, we demonstrated that the 3’UTR of RNGTT mRNA is methylated with m6a by the m6A writer methyltransferase 3 (METTL3). Knockdown of METTL3 resulted in reduced protein expression of RNGTT. Sequencing of capped mRNAs identified an underrepresentation of ribosomal protein mRNA overlapping with 5’ terminal oligopyrimidine (TOP) mRNAs, and genes are dysregulated when cytoplasmic capping is inhibited. Pathway analysis identified disruptions in the mTOR and p70S6K pathways. A reduction in RPS6 mRNA capping, protein expression, and phosphorylation was detected with METTL3 knockdown
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Virginia Commonwealth University, Department of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Richmond, USA (GRID:grid.224260.0) (ISNI:0000 0004 0458 8737)
2 The Ohio State University, Department of Cancer Biology and Genetics and Comprehensive Cancer Center, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943); The Ohio State University, Center for RNA Biology, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
3 The Ohio State University, Department of Internal Medicine, Division of Medical Oncology, The James Comprehensive Cancer Center, Columbus, USA (GRID:grid.261331.4) (ISNI:0000 0001 2285 7943)
4 Virginia Commonwealth University, Department of Internal Medicine, Division of Pulmonary Diseases and Critical Care Medicine, Richmond, USA (GRID:grid.224260.0) (ISNI:0000 0004 0458 8737); LUM University, Department of Medicine and Surgery, Casamassima, Italy (GRID:grid.224260.0)